Oxurion to Participate in Needham Virtual Healthcare Conference

     Oxurion to Participate in Needham Virtual Healthcare Conference 

Leuven, BELGIUM, Boston, MA, US - MARCH 28, 2022 – 8.00 AM CET  – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announces today that Tom Graney, Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 9:30 AM ET.

A live webcast and 90-day archive will be available in the “Investors” section of the Company’s website. 

 About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For more information, please contact:

Oxurion NVTom GraneyChief Executive OfficerTel: [phone] [e-mail]     Michaël DillenChief Business OfficerTel: [phone] [e-mail]

EUMEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel: [phone] [e-mail]   USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835 [e-mail]